 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...2122232425262728293031...100101» |
- |||| Phenomenal talk @RareOvarCancers, great questions @ovarcome! I'll add ●RAMP201 study (AVUTOMETINIB/ defactinib) is for ALL women with LGSOC (KRASm and WT) and ●exceptional response with trametinib/ letrozole, optimizing a precision medicine strategy by @Dr_R_Kurzrock (Twitter) - Jan 27, 2023
- | letrozole / Generic mfg.
Preclinical, Journal: Suppression of neurotransmission on gonadotropin-releasing hormone neurons in letrozole-induced polycystic ovary syndrome: A mouse model. (Pubmed Central) - Jan 27, 2023
Furthermore, we also found that letrozole-fed mice showed irregularity in the estrous cycle, increased body weight, and anovulation in female mice. These findings suggest that PCOS is an endocrine disorder that may directly affect the neurotransmitter system regulating GnRH neuronal activity at the hypothalamic level and impact reproductive physiology.
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P2/3 trial: Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome (clinicaltrials.gov) - Jan 27, 2023
P2/3, N=220, Completed, Sponsor: Services Institute of Medical Sciences, Pakistan
- | Phase classification: POWER: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (clinicaltrials.gov) - Jan 26, 2023
P2, N=83, Recruiting, Sponsor: Shayna Showalter, MD
These findings suggest that PCOS is an endocrine disorder that may directly affect the neurotransmitter system regulating GnRH neuronal activity at the hypothalamic level and impact reproductive physiology. Phase classification: P1 --> P2
- ||||||| Kisqali (ribociclib) / Novartis
Trial completion, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 25, 2023
P3, N=3246, Completed, Sponsor: Novartis Pharmaceuticals
Phase classification: P1 --> P2 Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
Journal, Tumor mutational burden, IO biomarker, Metastases: Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. (Pubmed Central) - Jan 25, 2023
P2
Genomic complexity detected by non-invasive profiling of bTMB and bCNB predicted poor outcomes in patients treated with ET and CDK4/6i and identified early disease progression before imaging. Novel treatment strategies including immunotherapy-based combinations should be investigated in this population.
- | letrozole / Generic mfg.
Preclinical, Journal: Therapeutic Potential of Selenium Nanoparticles on Letrozole-Induced Polycystic Ovarian Syndrome in Female Wistar Rats. (Pubmed Central) - Jan 25, 2023
It was depicted from the study that SeNPs reduce the upregulation of inflammatory cytokines that are interleukin 6 (IL-6), tumour necrosis factor α (TNF-α), and the interleukin 1 (IL-1). Our findings show that SeNPs, through their antioxidant and anti-inflammatory characteristics, alleviate letrozole-induced PCOS.
- || letrozole / Generic mfg.
Interesting to hear. Is that also the case with Letrozole? I’ve been recommended a turmeric supplement by my health team and it’s doing wonders for my joints. Would hate to give it up! (Twitter) - Jan 24, 2023
- | letrozole / Generic mfg., exemestane / Generic mfg.
Journal: The Effect of Metalloestrogens on the Effectiveness of Aromatase Inhibitors in a Hormone-Dependent Breast Cancer Cell Model. (Pubmed Central) - Jan 22, 2023
Our results confirm that exposure to metalloestrogens may negatively affect the effectiveness of hormone therapy with AI. Further studies are needed to fully explain the mechanism of these interactions.
- | letrozole / Generic mfg.
Journal: Letrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy. (Pubmed Central) - Jan 22, 2023
However, despite the promising findings reported by several studies, to date Letrozole is not yet officially mentioned in the guidelines for "Prevention and Treatment of moderate and severe ovarian hyperstimulation syndrome". In this scenario, the current study discusses Letrozole approaches scientifically available to prevent OHSS.
- | letrozole / Generic mfg.
Journal: Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation. (Pubmed Central) - Jan 22, 2023
Besides, icariin reduced lipid synthesis, which elicited stearoyl-Coenzyme A desaturase 1 (SCD1), fatty acid synthase (FASN), and acetyl-CoA (ACC). (4) Icariin showed an ameliorative effect on hepatic steatosis induced by HFD and letrozole, which was associated with improved fatty acid oxidation and reduced lipid accumulation in the liver.
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. (Pubmed Central) - Jan 22, 2023
P1
No subject demonstrated signs of drug induced liver injury and no subject showed serum folate level outside the normal range. Hence, our data suggests that a daily dose of 800 mg of EGCG alone or in combination with clomiphene citrate or letrozole (for 5 days) is well-tolerated and is not associated with liver toxicity or folate deficiency in reproductive-aged women.
- | metformin / Generic mfg., letrozole / Generic mfg.
Journal: Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue. (Pubmed Central) - Jan 21, 2023
Combined SeNPs and MET therapy could be potential therapeutic agent for PCOS-IR model via modulation of the PI3K/Akt pathway, enhancing anti-inflammatory and anti-oxidant properties and altered mitochondrial functions. HighlightsThe strong relationship between obesity, insulin resistance, and polycystic ovarian syndrome.Disturbance of the PI3K/Akt signaling pathway is involved in the progression of polycystic ovary syndrome-insulin resistance (PCOS-IR).In PCOS-IR rats, combined SeNPs and metformin therapy considerably alleviated IR by acting on the PI3K/Akt signaling pathway.The combination of SeNPs and metformin clearly repaired ovarian polycystic pathogenesis and improved hormonal imbalance in PCOS-IR rats.
- ||| letrozole / Generic mfg., Verzenio (abemaciclib) / Eli Lilly
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer https://t.co/PV5cbg6DdM This sounds really promising! (Twitter) - Jan 21, 2023
- |||| letrozole / Generic mfg., Perjeta (pertuzumab) / Roche
Clinical, Combination therapy: #HER2low #PathTwitter #BreastPath #SABCS22 It predicts response to neoadjuvant "Letrozole"in combination with dua HER2 blockade with transtuzumab and pertuzumab in early breast ca (Hormone positive, Her 2 positive) (Twitter) - Jan 19, 2023
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Jan 19, 2023
P2, N=388, Active, not recruiting, Sponsor: iOMEDICO AG
HighlightsThe strong relationship between obesity, insulin resistance, and polycystic ovarian syndrome.Disturbance of the PI3K/Akt signaling pathway is involved in the progression of polycystic ovary syndrome-insulin resistance (PCOS-IR).In PCOS-IR rats, combined SeNPs and metformin therapy considerably alleviated IR by acting on the PI3K/Akt signaling pathway.The combination of SeNPs and metformin clearly repaired ovarian polycystic pathogenesis and improved hormonal imbalance in PCOS-IR rats. Trial completion date: Jan 2023 --> Dec 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 18, 2023
P=N/A, N=109, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Jan 2023 --> Dec 2023 Trial completion date: Sep 2022 --> Sep 2023
- | letrozole / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Letrozole in Induction of Abortion of Anembryonic Pregnancy (clinicaltrials.gov) - Jan 18, 2023
P=N/A, N=96, Completed, Sponsor: Cairo University
Trial completion date: Sep 2022 --> Sep 2023 Recruiting --> Completed | Trial completion date: May 2022 --> Jan 2022 | Trial primary completion date: May 2022 --> Jan 2022
- | letrozole / Generic mfg.
Preclinical, Journal: Effects of electroacupuncture on the kisspeptin-gonadotropin-releasing hormone (GnRH) /luteinizing hormone (LH) neural circuit abnormalities and androgen receptor expression of kisspeptin/neurokinin B/dynorphin neurons in PCOS rats. (Pubmed Central) - Jan 18, 2023
Improvement in the reproductive hallmarks of PCOS rats via EA may be achieved by regulating the kisspeptin-GnRH/LH circuit via androgen activity attenuation. Thus, the results provide an experimental basis for acupuncture as an adjuvant medical therapy on PCOS.
- | letrozole / Generic mfg.
Journal: Macrophages in juvenile pig testis: Link with increase in Sertoli cells induced by estradiol suppression. (Pubmed Central) - Jan 17, 2023
However, the macrophage layer beneath the tunica albuginea was denser and thicker in the letrozole-treated animals than in their vehicle-treated littermates. This suggests that macrophages might be involved in the letrozole-induced prolongation of Sertoli cell proliferation.
- | letrozole / Generic mfg.
Journal: Live birth associated with peak serum estradiol concentrations in letrozole intrauterine insemination (IUI) cycles. (Pubmed Central) - Jan 13, 2023
In letrozole ovulation induction cycles followed by intrauterine insemination, lower LBR and clinical pregnancy rates were found in women with lower E2 concentrations compared with higher E2 concentrations at the 25, 50, and 75 percentile E2 concentration quartiles. Where possible, delaying HCG trigger until E2 concentration rises following aromatase inhibition and approaches physiologic periovulatory concentration may improve pregnancy rates with letrozole followed by intrauterine insemination.
- | Ibrance (palbociclib) / Pfizer
Retrospective data, Journal: On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates. (Pubmed Central) - Jan 13, 2023
P3
On-treatment dNLR significantly predicted PFS in patients with HR-positive, HER2-negative ABC receiving palbociclib and endocrine treatment. Additionally, we observed putative systemic immune responses elicited by palbociclib, suggesting immunologic changes upon CDK4/6 inhibitor treatment.
- | metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: The effects of melatonin and metformin on histological characteristics of the ovary and uterus in letrozole-induced polycystic ovarian syndrome mice: A stereological study. (Pubmed Central) - Jan 10, 2023
It appears that metformin and melatonin could restore the PCOS phenotype including estrus cycle irregularity, high testosterone level, and ovarian and uterine micromorphology to the control levels. However, the 2 treatments had similar effects on the examined parameters.
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Jan 10, 2023
P1b, N=25, Recruiting, Sponsor: University of California, San Francisco
However, the 2 treatments had similar effects on the examined parameters. Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: PHERGain: Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (clinicaltrials.gov) - Jan 10, 2023
P2, N=377, Active, not recruiting, Sponsor: MedSIR
Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
- |||||| letrozole / Generic mfg.
New trial: SMART Protocol vs Antagonist Protocol in IVF (clinicaltrials.gov) - Jan 10, 2023
P=N/A, N=3600, Active, not recruiting, Sponsor: Clinique Ovo
- || ipatasertib (RG7440) / Roche
Enrollment closed, Metastases: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) (clinicaltrials.gov) - Jan 9, 2023
P1, N=77, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023 Recruiting --> Active, not recruiting
- || Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
P2 data, Journal: A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). (Pubmed Central) - Jan 8, 2023
P2
RNA sequencing and Ki67 data indicated potent anti-proliferative effects of study treatments. ClinicalTrials.gov- NCT02907918.
- | letrozole / Generic mfg., menotropin / Generic mfg.
Retrospective data, Journal: Retrospective analysis: The application of human menopausal gonadotropin combined with letrozole for IUI in patients undergoing artificial insemination by husband due to unexplained or mild male factors. (Pubmed Central) - Jan 7, 2023
Moreover, ovarian stimulation with HMG+LE was the only beneficial factor significantly associated with clinical pregnancy (OR 1.929, 95% CI 1.068~3.485, P=0.029) and live birth (OR 2.255, 95% CI 1.188~4.282, P=0.013). Ovarian stimulation using HMG combined with LE can increase the clinical outcomes (live birth and clinical pregnancy) among infertile patients undergoing AIH due to explained or mild male factors.
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2HR breast cancer. (Pubmed Central) - Jan 6, 2023
P2
Furthermore, CALML5 was revealed to be a risk factor in the treatment of HER2/HR breast cancer and the usage of dalpiciclib might overcome the drug resistance to pyrotinib + tamoxifen due to CALML5 expression. Our study provided evidence that the usage of dalpiciclib in the treatment of HER2/HR breast cancer could partially abrogate the estrogen signaling pathway activation caused by anti-HER2 therapy and revealed that CALML5 could serve as a risk factor in the treatment of HER2/HR breast cancer.
- COMPARING CARDIOVASCULAR RISK PROFILE AMONG AROMATASE INHIBITORS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS : A PHARMACOVIGILANCE ANALYSIS (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_8637;
AIs are observed to be associated with higher rates of CV AEs compared to SERMs. Further studies are warranted to establish the CV risk profile of these agents.
- Verzenio (abemaciclib) / Eli Lilly
CANCER THERAPY-RELATED ATRIAL FIBROSIS DIAGNOSED WITH MULTI-MODALITY IMAGING: A CASE REPORT (Poster Hall_Hall F) - Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_4997;
Atrial fibrosis and dysfunction could be early features of CTRCD that can be identified before the overt onset of decompensated heart failure. This case report highlights the utility of advanced cardiac imaging techniques to identify CTRCT.
- |||| letrozole / Generic mfg., Kadcyla (ado-trastuzumab emtansine) / Roche
Clinical: #HER2DX ERBB2 predicts response to T-DM1, and also neoadjuvant HP+letrozole in a prior study (https://t.co/GRD7VzTiWA) ERBB2 mRNA predicts response to T-DM1 within HER2+ is not new. Check EMILIA and TH3RESA trials! In our study, ERBB2 also predicted better PFS and better OS! (Twitter) - Dec 29, 2022
- | letrozole / Generic mfg.
Preclinical, Journal: Beneficial effects of Teucrium polium hydroalcoholic extract on letrozole-induced polycystic ovary syndrome (PCOS) in rat model. (Pubmed Central) - Dec 28, 2022
Histological studies of ovaries in the metformin and T. polium groups exhibited normal follicular development with fewer and smaller cystic follicles than those in the PCOS group. The hydroalcoholic extract of T. polium improves serum levels of sex hormones, restores ovarian morphology in PCOS-induced rats, and is a good candidate for further clinical trials.
- | letrozole / Generic mfg.
Journal: Effects of letrozole co-treatment on the cumulative live-birth rate among normal responders in gonadotropin-releasing hormone antagonist cycles. (Pubmed Central) - Dec 27, 2022
However, letrozole may increase the rate of embryo implantation and may reduce the requirement for exogenous gonadotrophins and, consequently, the cost of an IVF treatment cycle. In addition, the decreased estradiol level in the ovarian simulation by letrozole supports letrozole can be a safe solution for fertility preservation in estrogen-related cancer patients.
- | letrozole / Generic mfg.
Journal: The Effect of the Time Interval From Sperm Processing to Intrauterine Insemination on the Pregnancy Outcomes of Infertile Women. (Pubmed Central) - Dec 27, 2022
The results of this study suggest that SP-IUI intervals evaluated in this study do not vary in terms of pregnancy rate or adverse pregnancy outcomes in IUI with normal male partner semen analysis. Hence, infertile couples can be flexible in the collection of semen specimens without time and site (at home or hospital) limitations.
- | letrozole / Generic mfg.
Journal: Ovulation induction using sequential letrozole/gonadotrophin in infertile women with PCOS: a randomized controlled trial. (Pubmed Central) - Dec 25, 2022
Hence, infertile couples can be flexible in the collection of semen specimens without time and site (at home or hospital) limitations. The data suggest that the sequential letrozole/HMG protocol may be superior to the letrozole alone protocol in terms of ovulation induction and pregnancy promotion among infertile women with PCOS.
- | letrozole / Generic mfg.
Preclinical, Journal: Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model. (Pubmed Central) - Dec 24, 2022
Human PBMCs treated with letrozole/estrogen combinations did not demonstrate an AI-specific gene expression pattern, suggesting AIIA-mediated pathogenesis through other cell types. Collectively, these data identify an AI-induced stimulation of disease pathology and suggest that AIIA pathogenesis may not be mediated by estrogen deficiency, as previously hypothesized.
- | letrozole / Generic mfg.
Retrospective data, Journal: Letrozole as premedication of high intensity focused ultrasound treatment of uterine fibroids: A retrospective observation study. (Pubmed Central) - Dec 24, 2022
Letrozole as a pretreatment medication before HIFU treatment might increase the energy efficiency and treatment efficiency of its ablation of uterine leiomyoma, especially for fibroid over 10 cm. Future study of larger patient number is needed to confirm our results.
- | metformin / Generic mfg., letrozole / Generic mfg.
Biomarker, Journal: Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. (Pubmed Central) - Dec 24, 2022
P2
Metformin may exert anti-cancer activity by decreasing the circulating estradiol, leptin, and insulin. Metformin might represent a safe and promising adjuvant therapy to letrozole in overweight/obese postmenopausal women with breast cancer.
- | letrozole / Generic mfg.
Journal: Letrozole increases preantral follicle growth and decreases estradiol production without impairing follicle survival. (Pubmed Central) - Dec 24, 2022
Letrozole may be useful for fertility preservation of patients with estrogen-dependent cancers such as breast cancer and various other cancers. Whether letrozole has a direct effect in reducing OHSS requires further investigation.
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment change, Trial withdrawal, Combination therapy, Metastases: Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (clinicaltrials.gov) - Dec 23, 2022
P1, N=0, Withdrawn, Sponsor: Medical College of Wisconsin
Whether letrozole has a direct effect in reducing OHSS requires further investigation. N=44 --> 0 | Suspended --> Withdrawn
- | letrozole / Generic mfg.
Trial primary completion date: Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation (clinicaltrials.gov) - Dec 22, 2022
P4, N=184, Recruiting, Sponsor: Rachel Mejia
N=44 --> 0 | Suspended --> Withdrawn Trial primary completion date: Oct 2022 --> Apr 2023
- || Clinical, Retrospective data, Review, Journal: Impact of anti-oestrogen therapy on lipoprotein(a) in postmenopausal women: a systematic review and meta-analysis of double-blind placebo-controlled clinical studies. (Pubmed Central) - Dec 22, 2022
Trial primary completion date: Oct 2022 --> Apr 2023 This observation is of both clinical and pathophysiological relevance, also in view that the identification of molecular determinants and cellular pathways implicated in Lp(a) synthesis and metabolism is still of concern as a critical issue in lipidology and CV prevention.
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date: POETIC-A: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (clinicaltrials.gov) - Dec 21, 2022
P3, N=2500, Recruiting, Sponsor: Institute of Cancer Research, United Kingdom
This observation is of both clinical and pathophysiological relevance, also in view that the identification of molecular determinants and cellular pathways implicated in Lp(a) synthesis and metabolism is still of concern as a critical issue in lipidology and CV prevention. Trial completion date: Sep 2028 --> Mar 2032 | Trial primary completion date: Mar 2026 --> Sep 2030
- ||| Clinical: Pts were randomly assigned to receive either ribociclib 600 mg 3 weeks on,1 week off plus letrozole or anastrozole and goserelin, or the investigators choice of either docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine-PFS 24 vs 12.3months. (Twitter) - Dec 20, 2022
- |||| Clinical: pre- or perimenopausal women with HR+/HER2– untreated breast ca,combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitor first-line ribociclib, combined with either letrozole or anastrozole+goserelin, was associated with a doubling of PFS,compared with combination chemo-cost (Twitter) - Dec 20, 2022
- | letrozole / Generic mfg.
Preclinical, Journal: In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. (Pubmed Central) - Dec 20, 2022
The flow cytometry results revealed that L + L enhanced the apoptosis rate in both MCF-7 and MDA-MB-231 cell lines compared with the letrozole (L), letrozole-loaded niosome (L), and control sample. Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells.
- || Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole (clinicaltrials.gov) - Dec 19, 2022
P=N/A, N=42, Active, not recruiting, Sponsor: Pfizer
Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells. Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Nov 2025 | Trial primary completion date: Dec 2022 --> Nov 2025
- | metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: Ketogenic diet restores hormonal, apoptotic/proliferative balance and enhances the effect of metformin on a letrozole-induced polycystic ovary model in rats. (Pubmed Central) - Dec 18, 2022
Our results indicate that the KD has a protective role against PCO in rats, especially when combined with metformin. This study reveals a potential therapeutic role of the KD in PCO, which could prompt valuable future clinical applications.